Construction of cancer pathways for personalized medicine | Presented By Date Construction of cancer pathways for personalized medicine Predictive, Preventive.

Slides:

Advertisements

Similar presentations

Molecular Systems Biology 3; Article number 140; doi: /msb

Advertisements

Predictive Analysis of Gene Expression Data from Human SAGE Libraries Alexessander Alves* Nikolay Zagoruiko + Oleg Okun § Olga Kutnenko + Irina Borisova.

Oncomine Database Lauren Smalls-Mantey Georgia Institute of Technology June 19, 2006 Note: This presentation contains animation.

Prof. Carolina Ruiz Computer Science Department Bioinformatics and Computational Biology Program WPI WELCOME TO BCB4003/CS4803 BCB503/CS583 BIOLOGICAL.

Data integration across omics landscapes Bing Zhang, Ph.D. Department of Biomedical Informatics Vanderbilt University School of Medicine

Linking Genetic Profiles to Biological Outcome Paul Fogel Consultant, Paris S. Stanley Young National Institute of Statistical Sciences NISS, NMF Workshop.

Cluster analysis of networks generated through homology: automatic identification of important protein communities involved in cancer metastasis Jonsson.

Gene expression analysis summary Where are we now?

Microarrays and Cancer Segal et al. CS 466 Saurabh Sinha.

ONCOMINE: A Bioinformatics Infrastructure for Cancer Genomics

Multidimensional Analysis If you are comparing more than two conditions (for example 10 types of cancer) or if you are looking at a time series (cell cycle.

Introduction to molecular networks Sushmita Roy BMI/CS 576 Nov 6 th, 2014.

Gene Set Enrichment Analysis Petri Törönen petri(DOT)toronen(AT)helsinki.fi.

Comprehensive Gene Expression Analysis of Prostate Cancer Reveals Distinct Transcriptional Programs Associated With Metastatic Disease Kevin Paiz-Ramirez.

Introduction The goal of translational bioinformatics is to enable the transformation of increasingly voluminous genomic and biological data into diagnostics.

Paola CASTAGNOLI Maria FOTI Microarrays. Applicazioni nella genomica funzionale e nel genotyping DIPARTIMENTO DI BIOTECNOLOGIE E BIOSCIENZE.

Gaussian Processes for Transcription Factor Protein Inference Neil D. Lawrence, Guido Sanguinetti and Magnus Rattray.

Malignant Melanoma and CDKN2A

Gene expression profiling identifies molecular subtypes of gliomas

A Bioinformatics Meta-analysis of Differentially Expressed Genes in Colorectal Cancer Simon Chan, Thursday Trainee Seminar – October 11.

Transcription Factor Binding Motifs, Chromosome mapping and Gene Ontology analysis on Cross-platform microarray data from bladder cancer. Apostolos Zaravinos.

Cis-regulation Trans-regulation 5 Objective: pathway reconstruction.

Radiogenomics in glioblastoma multiforme

From motif search to gene expression analysis

A systems biology approach to the identification and analysis of transcriptional regulatory networks in osteocytes Angela K. Dean, Stephen E. Harris, Jianhua.

Genetic Regulatory Network Inference Russell Schwartz Department of Biological Sciences Carnegie Mellon University.

Table S1. Characteristics of breast tumor and normal breast tissue samples. Relevant characteristics of breast tumor and normal breast tissue samples analyzed.

BioQUEST / SCALE-IT Module From Omics Data to Knowledge Case 1: Microarrays Namyong Lee Minnesota State University, Mankato Matthew Macauley Clemson University.

Finish up array applications Move on to proteomics Protein microarrays.

BIOMARKERS Diagnostics and Prognostics. OMICS Molecular Diagnostics: Promises and Possibilities, p. 12 and 26.

Reconstructing gene networks Analysing the properties of gene networks Gene Networks Using gene expression data to reconstruct gene networks.

Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.

Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets Node Patient 1Patient 2Patient 3 Primary Mets.

1 FINAL PROJECT- Key dates –last day to decided on a project * 11-10/1- Presenting a proposed project in small groups A very short presentation (Max.

COMPUTATIONAL ANALYSIS OF MULTILEVEL OMICS DATA FOR THE ELUCIDATION OF MOLECULAR MECHANISMS OF CANCER Presented by Azeez Ayomide Fatai Supervisor: Junaid.

Differential analysis of Eigengene Networks: Finding And Analyzing Shared Modules Across Multiple Microarray Datasets Peter Langfelder and Steve Horvath.

Gene Expression Analysis. 2 DNA Microarray First introduced in 1987 A microarray is a tool for analyzing gene expression in genomic scale. The microarray.

Gene Expression and Networks. 2 Microarray Analysis Supervised Methods -Analysis of variance -Discriminate analysis -Support Vector Machine (SVM) Unsupervised.

Bioinformatics MEDC601 Lecture by Brad Windle Ph# Office: Massey Cancer Center, Goodwin Labs Room 319 Web site for lecture:

Support Vector Machine Data Mining Olvi L. Mangasarian with Glenn M. Fung, Jude W. Shavlik & Collaborators at ExonHit – Paris Data Mining Institute University.

Pathway: a collection of genes, proteins, and /or small molecules that modulate a cellular process or disease state Growing demand in biological sciences.

While gene expression data is widely available describing mRNA levels in different cancer cells lines, the molecular regulatory mechanisms responsible.

Class 23, 2001 CBCl/AI MIT Bioinformatics Applications and Feature Selection for SVMs S. Mukherjee.

Lecture 11. Topics in Omic Studies (Cancer Genomics, Transcriptomics and Epignomics) The Chinese University of Hong Kong CSCI5050 Bioinformatics and Computational.

Molecular Classification of Cancer Class Discovery and Class Prediction by Gene Expression Monitoring.

Gene expression. Gene Expression 2 protein RNA DNA.

Case Study: Characterizing Diseased States from Expression/Regulation Data Tuck et al., BMC Bioinformatics, 2006.

Eigengenes as biological signatures Dr. Habil Zare, PhD PI of Oncinfo Lab Assistant Professor, Department of Computer Science Texas State University 5.

Gene Set Analysis using R and Bioconductor Daniel Gusenleitner

Different microarray applications Rita Holdhus Introduction to microarrays September 2010 microarray.no Aim of lecture: To get some basic knowledge about.

Simultaneous identification of causal genes and dys-regulated pathways in complex diseases Yoo-Ah Kim, Stefan Wuchty and Teresa M Przytycka Paper to be.

Eigengenes as biological signatures Dr. Habil Zare, PhD PI of Oncinfo Lab Assistant Professor, Department of Computer Science Texas State University 3.

David Amar, Tom Hait, and Ron Shamir

FINAL PROJECT- Key dates

Gene expression.

A Functional Map of Oncogenic States for Breast Cancer

M. Fu, G. Huang, Z. Zhang, J. Liu, Z. Zhang, Z. Huang, B. Yu, F. Meng

Ingenuity Knowledge Base

Gene expression changes in damaged osteoarthritic cartilage identify a signature of non-chondrogenic and mechanical responses S.L. Dunn, J. Soul, S.

Loyola Marymount University

Project Work Problem formulation.

Characteristics of tissue‐specific co‐expression networks (CNs)‏

Loyola Marymount University

Loyola Marymount University

Functional classification and visualization of differentially expressed genes. Functional classification and visualization of differentially expressed.

Loyola Marymount University

CD4+CLA+CD103+ T cells from human blood and skin share a transcriptional profile. CD4+CLA+CD103+ T cells from human blood and skin share a transcriptional.

Loyola Marymount University

High-risk neuroblastoma molecular subtypes classification and inference of master regulators. High-risk neuroblastoma molecular subtypes classification.

Distinct subtypes of CAFs are detected in human PDAC

Presentation transcript:

Construction of cancer pathways for personalized medicine | Presented By Date Construction of cancer pathways for personalized medicine Predictive, Preventive and Personalized Medicine & Molecular Diagnostics Dr. Anton Yuryev Nov 4, 2014

Construction of cancer pathways for personalized medicine | Curse of Dimensionality of OMICs data: We will never have enough patient samples to calculate robust signatures from large scale molecular profiling data 2 signature size # patients error rate Hua et al. Optimal number of features as a function of sample size for various classification rules. Bioinformatics Fig.3 Optimal feature size versus sample size for Polynomial SVM classifier. nonlinear model, correlated feature, G=1,  =  2 is set to let Bayers error be 0.05

Construction of cancer pathways for personalized medicine | Mathematical requirements for short signature size vs. Biological reality Mathematical requirementBiological reality Signature size must be genesTypical cancer transcriptomics profile has differentially expressed genes with p-value < Increasing number of samples above 200 does not change optimal signature size Typical cancer dataset has not more than 100 patients. Increasing number of patients results in finding different cancer sub-types each having small number of samples Error rate and robustness of signatures from uncorrelated feature is better than from correlated features Most DE genes are correlated due to transcriptional linkage and different TFs regulated by only few biological pathways We can use prior knowledge about transcriptional regulation to select most uncorrelated features, e.g. genes controlled by different TFs in different pathways 3

Construction of cancer pathways for personalized medicine | 4 Our solution: Pathway Activity signature SNEA (sub-network enrichment analysis) -> pathway analysis Hanahan & Weinberg. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74

Construction of cancer pathways for personalized medicine | Common misconception 5 Differential Expression of its components Pathway activity Differential Expression of its expression targets

Construction of cancer pathways for personalized medicine | STEP1: SNEA calculating activity transcriptional activity of upstream regulators 6 Input: DE fold changes + prior knowledgebase of known expression regulation events Molecular networks in microarray analysis. Sivachenko A, Yuryev A, Daraselia N, Mazo I. J Bioinform Comp. Biol SNEAReverse Causal Reasoning Mann-Whitney enrichment testFisher’s overlap test

Construction of cancer pathways for personalized medicine | Pathway Studio Knowledgebase for SNEA powered by Elsevier NLP 7 > Internal Documents Subscribed Titles 613 Elsevier journals 23,641,270 Pubmed abstracts from >9,500 journals 884 non-Elsevier journals Custom data can be imported into dedicated PS instance Public databases >3,500,000 full-text articles 27, ,365 Expression: Protein->Protein Promoter Binding: Protein TF->Protein

Construction of cancer pathways for personalized medicine | Example of expression regulators and Cell processes identified by SNEA in lung cancer patient

Construction of cancer pathways for personalized medicine | 9 STEP2: Mapping expression regulators on pathways Hypoxia->EMT Hypoxia->Angiogenesis Blue highlight – expression regulators in Lung cancer patient identified by SNEA

Construction of cancer pathways for personalized medicine | Gallbladder/Liver cancer Lung cancer #1 Lung cancer #2 Breast cancer metastasis in lung Colon cancer metastasis in liver 10 Personalized Hematology-Oncology of Wake Forest 5 cancer patients analyzed with SNEA to build cancer pathways

Construction of cancer pathways for personalized medicine | Upper estimate: 10 hallmarks X 250 tissues = 2,500 In practice some pathways may be common for all tissues. Example: Cell cycle pathways 11 How many cancer pathways must be built? Red highlight – Activated SNEA regulators

Construction of cancer pathways for personalized medicine | 12 Cancer pathways: Insights to cancer biology EGFR activation by apoptotic clearance (wound healing pathway) Red highlight – Activated SNEA regulators Apoptotic debris

Construction of cancer pathways for personalized medicine | 13 TGF-  autocrine loop sustains EMT

Construction of cancer pathways for personalized medicine | 14 Avoiding immune response: N1->N2 polarization Highlights – SNEA regulators from different patients

Construction of cancer pathways for personalized medicine | 15 How to select anti-cancer drugs in Pathway Studio

Construction of cancer pathways for personalized medicine | Conclusions: pathways containing 2,796 proteins provide mechanism for advanced cancer in 5 patients Pathways explain about 50% (378) of all top 100 SNEA regulators indentified in five patients Pathways are validated by: Scientific literature Patient microarray data Efficacy of personalized therapy